Wednesday, February 13, 2013

Seeking Alpha: Lundbeck Could Cheer Up Patient Investors

H.Lundbeck (HLUYY.PK) isn't going to be an especially familiar name for many readers, as this Danish pharmaceutical company has largely sold through licensing partners in the United States. That said, this CNS specialist was the brains behind Forest Labs' (FRX) highly successful depression drug Lexapro, and the company has some particularly interesting drugs in its pipeline. While the company's go-to-market strategy is still a work in progress and patent expirations are likely going to cut deeply into cash flows in the short term, this looks like a potentially undervalued name to consider.

Please read the full article here:
Lundbeck Could Cheer Up Patient Investors

No comments: